@lovethespeccies, the interim analysis includes much more than just the three biomarkers, which are all important, and especially this last one we're still waiting on (!), but as Quiltman pointed out, the NfL marker is not a do or die proposition - other factors come into question, like how the patients are faring in all sorts of ways. My point is why did the PI ask for this interim analysis? But certainly be cautious, nothing is guaranteed.
Ann: Cohort 3 Pharmacokinetics in MND Patients Completed, page-120
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.85M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 175000 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 20000 | 1 |
View Market Depth
| Last trade - 09.15am 01/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |
Day chart unavailable